Highlights Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
23.25 ^USD	+0.19%		+2.69%	+12.42%

04-23	Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target	MT
03-14	Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	03-14	CI
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Cartesian Therapeutics, Inc. Establishes New Corporate Headquarters and mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	03-05	CI
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	01-08	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Cartesian Therapeutics, Inc. acquired Selecta Biosciences, Inc. for approximately $380 million, in a reverse merger transaction.	11-12	CI
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement	31/10/23	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/08/23	CI
Selecta Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Top Premarket Gainers	21/03/23	MT
Selecta Biosciences, Inc Announces Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint	21/03/23	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/03/23	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	02/03/23	CI
Selecta Biosciences Signs Licensing Deal With Astellas for IgG Protease Candidate Xork; Shares Rise	09/01/23	MT
Selecta Biosciences, Inc. and Astellas Pharma Inc. Announce Exclusive Licensing and Development Agreement for Xork IgG Protease	09/01/23	CI
Selecta Biosciences Picks New Candidate for Kidney Disease Program	14/12/22	MT
Selecta Biosciences Announces Next Generation Iga Protease Clinical Candidate Selection for Iga Nephropathy Program	14/12/22	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22	CI
Selecta Biosciences, Inc. Completes Enrollment in Its Dissolve II Phase 3 Clinical Trial of SEL-212 for the Treatment of Chronic Refractory Gout	30/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Highlights

Filters